Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19637369 | 0.69 | HTT (0.35) | HTT | |
| SCHEMBL14364533 | 0.67 | LMNA (0.38) | LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10972974 | 0.67 | TDP1 (0.35) | HTTALDH1A1 | |
| SCHEMBL19637255 | 0.67 | HTT (0.34) | HTT | |
| SCHEMBL15747526 | 0.66 | LMNA (0.36) | HTTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19637079 | 0.65 | HTT (0.32) | HTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10522415 | 0.64 | GLP1R (0.36) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL21895750 | 0.63 | SMN1; SMN2 (0.41) | HTTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10647312 | 0.63 | LMNA (0.44) | HTTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19637432 | 0.62 | KDM4E (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |